Pfizer’s FDA-approved interchangeable
biosimilar to
Humira® (adalimumab)
Injection: 40 mg/0.8 mL, 20 mg/0.4 mL
ABRILADA. Let’s go.
Not actual patient.
Are you starting treatment with ABRILADA?
Are you switching to ABRILADA from Humira?
If eligible, you may pay as little as $0 for ABRILADA treatment.
Enrollment required. Limits, terms, and conditions apply.*
ABRILADA IS APPROVED TO
REDUCE THE SIGNS AND SYMPTOMS OF: |
|
|
Moderate to severe rheumatoid arthritis (RA) in adults. ABRILADA can be used alone, with methotrexate, or with certain other medicines. ABRILADA may prevent further damage to your bones and joints and may help your ability to perform daily activities. |
|
Moderate to severe polyarticular juvenile idiopathic arthritis (JIA) in children 2 years of age and older. ABRILADA can be used alone or with methotrexate. |
|
Psoriatic arthritis (PsA) in adults. ABRILADA can be used alone or with certain other medicines. ABRILADA may prevent further damage to your bones and joints and may help your ability to perform daily activities. |
|
Ankylosing spondylitis (AS) in adults. |
|
Moderate to severe hidradenitis suppurativa (HS) in adults. |
TREAT: |
|
|
Moderate to severe Crohn’s disease (CD) in adults and children 6 years of age and older. |
|
Moderate to severe ulcerative colitis (UC) in adults. It is not known if adalimumab products are effective in people who stopped responding to or could not tolerate anti-TNF medicines. |
|
Moderate to severe chronic plaque psoriasis (Ps) in adults who are ready for systemic therapy or phototherapy, and are under the care of a doctor who will decide if other systemic therapies are less appropriate. |
|
Uveitis (UV) in adults: non-infectious intermediate (middle part of the eye), posterior (back of the eye), and panuveitis (all parts of the eye). |